Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study.

Autor:	Mut SE; University of Kyrenia, Faculty of Medicine, Department of Neurology, Kyrenia, Northern Cyprus., Selcuk F; European University of Lefke, Vocational school of Health Services, Lefke, Northern Cyprus, Mersin, Turkey., İncirli SU; Dr Burhan Nalbantoglu State Hospital, Department of Neurology, Nicosia, Northern Cyprus., Delibas S; University of Kyrenia, Faculty of Medicine, Kyrenia, Northern Cyprus.
Jazyk:	angličtina
Zdroj:	Clinical neuropharmacology [Clin Neuropharmacol] 2024 Jul-Aug 01; Vol. 47 (4), pp. 109-112. Date of Electronic Publication: 2024 May 14.
DOI:	10.1097/WNF.0000000000000596
Abstrakt:	Objectives: Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative progressive disease of central nervous system that mostly affects young adults. (1) Because of involvement of spinal cord and brain, lower urinary dysfunction symptoms are commonly encountered. MS patients mostly show overactive bladder symptoms like urgency, frequent daytime urination, and urgency incontinence. Among MS patients, antimuscarinic therapy is the first-line treatment with overactive bladder symptoms as well as in general population yet 30% of the patients show insufficient improvement or intolerance to the treatment (2). In our study, our aim is to evaluate the efficacy and safety of mirabegron add-on treatment in MS patients after inadequate response to antimuscarinic monotherapy. Methods: University of Kyrenia and Dr Burhan Nalbantoglu State hospital's databases were screened for the study. Seventy patients who were residents diagnosed with MS according to McDonald criteria were questioned. Among these patients, a total of 22 of them were included in the study. Inclusion criteria was at least 3 years of MS diagnosis, score of <6 at Expanded Disability Status Scale, and a score of ≥3 at Overactive Bladder Symptom Score Scale. Results: Among selected patients, 10 mg solifenacin treatment was daily started and followed for 4 weeks. Mirabegron add-on treatment was initiated to the 11 patient who had inadequate improvement in overactive bladder symptom score. After mirabegron add-on treatment among 11 patient, there was a sufficient improvement in overactive bladder symptom score ( P < 0.008). Conclusions: In our study, we have found that antimuscarinic and mirabegron combination causes improved efficacy for overactive bladder in MS population. Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu